Comparison · NCT04146896-sae
NYX-2925 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NYX-2925 vs Placebo: serious adverse events. Trial comparisons, record NCT04146896-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04146896-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00877 | 0.00155 | 0.048 | wilson | |
| Risk in group 2 | 0.0526 | 0.0243 | 0.11 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0439 | -0.102 | 0.00452 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.167 | 0.0204 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 0.159 | 0.0189 | 1.34 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on NYX-2925 than on Placebo | 22.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NYX-2925 | NYX-2925 50 mg QD~NYX-2925 50 mg: NYX-2925 administered orally | 1 | 114 | EG000 |
| Group 2 | Placebo | Placebo QD~Placebo: Placebo administered orally | 6 | 114 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Treatment emergent adverse events are defined as the start of the event occurring on or after the date of first dispensed study drug (Day 1, Baseline Visit) and before or on the last dose (Week 12). The protocol required adverse events to be followed to resolution of the adverse event.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
- NCT number
- NCT04146896
- Phases
- PHASE2
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- NYX-2925 50 mg, Placebo
- Lead sponsor
- Aptinyx
- Results first posted
- 2023-04-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04146896?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04146896-sae